NCT07461454 2026-03-10YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast CancerMediLink Therapeutics (Suzhou) Co., Ltd.Phase 3 Not yet recruiting376 enrolled
NCT07441512 2026-03-02A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA MutationZhejiang Cancer HospitalPhase 2 Not yet recruiting26 enrolled